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Association between hyperuricemia and metabolic syndrome in patients
suffering from bipolar disorder
Abstract

Background: Clinical studies have shown that bipolar patients have increased serum uric acid levels. High
serum uric acid levels could play a role contributing to high prevalence of metabolic syndrome. Metabolic
syndrome is known to increase the risk of developing a number of life threatening diseases including coronary
heart disease, hypertension, and type 2 diabetes. This study investigated the association between
hyperuricemia and metabolic syndrome and its components in individuals suffering from bipolar disorders.
Methods: This study recruited 318 inpatients suffering from bipolar disorders from Beijing Hui-Long-Guan
Hospital in China and 160 healthy subjects from the same region as the controls. We used National
Cholesterol Education Program Adult Treatment Panel III Adapted criteria (NCEP ATP-III A) for the
diagnosis of metabolic syndrome. Hyperuricemia was determined as serum uric acid level above 420 μmol/L
in men and 360 μmol/L in women (N Engl J Med 359(17):1811-1821, 2008).
Results: Among 318 bipolar patients, there was higher prevalence of metabolic syndrome (42.5%) and
hyperuricemia (27.7%) than healthy controls (21.9 and 11.9%). Bipolar patients with metabolic syndrome
had increased prevalence of hyperuricemia (OR = 3.0, CI95 [1.7-5.4]). Hypertriglyceridemia and larger waist
circumference (WC) were associated with hyperunicemia (OR = 1.8, CI95 [1.1-3.1], OR = 1.9, CI95
[1.1-3.4]). Hyperuricemia was associated with metabolic syndrome in bipolar patients (p < 0.001) and
especially with hypertriglyceridemia (OR = 1.9, CI95 [1.1-3.1] and increased WC (OR = 2.1 [1.2-4.0]).
Bipolar patients over 50 years of age and hyperuricemia were highly prone to develop metabolic syndrome
(OR = 14.0, CI95 [5.0-39.0]).
Conclusions: Hyperuricemia was highly associated with development of metabolic disorder particularly for
aged patients suffering from bipolar disorders. Early prevention of hyperuricemia and metabolic syndrome
may lead better life for bipolar patients when they get older.
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from bipolar disorder
Jingxu Chen1†, Hongmei Chen1†, Junhui Feng2, Ligang Zhang1, Juyan Li1, Ran Li1, Shaoli Wang1, Ian Wilson3,
Alison Jones3, Yunlong Tan1, Fude Yang1* and Xu-Feng Huang3*

Abstract
Background: Clinical studies have shown that bipolar patients have increased serum uric acid levels. High serum
uric acid levels could play a role contributing to high prevalence of metabolic syndrome. Metabolic syndrome is
known to increase the risk of developing a number of life threatening diseases including coronary heart disease,
hypertension, and type 2 diabetes. This study investigated the association between hyperuricemia and metabolic
syndrome and its components in individuals suffering from bipolar disorders.
Methods: This study recruited 318 inpatients suffering from bipolar disorders from Beijing Hui-Long-Guan Hospital
in China and 160 healthy subjects from the same region as the controls. We used National Cholesterol Education
Program Adult Treatment Panel III Adapted criteria (NCEP ATP-III A) for the diagnosis of metabolic syndrome.
Hyperuricemia was determined as serum uric acid level above 420 μmol/L in men and 360 μmol/L in women (N
Engl J Med 359(17):1811–1821, 2008).
Results: Among 318 bipolar patients, there was higher prevalence of metabolic syndrome (42.5%) and
hyperuricemia (27.7%) than healthy controls (21.9 and 11.9%). Bipolar patients with metabolic syndrome had
increased prevalence of hyperuricemia (OR = 3.0, CI95 [1.7–5.4]). Hypertriglyceridemia and larger waist circumference
(WC) were associated with hyperunicemia (OR = 1.8, CI95 [1.1–3.1], OR = 1.9, CI95 [1.1–3.4]). Hyperuricemia was
associated with metabolic syndrome in bipolar patients (p < 0.001) and especially with hypertriglyceridemia
(OR = 1.9, CI95 [1.1–3.1] and increased WC (OR = 2.1 [1.2–4.0]). Bipolar patients over 50 years of age and
hyperuricemia were highly prone to develop metabolic syndrome (OR = 14.0, CI95 [5.0–39.0]).
Conclusions: Hyperuricemia was highly associated with development of metabolic disorder particularly for
aged patients suffering from bipolar disorders. Early prevention of hyperuricemia and metabolic syndrome
may lead better life for bipolar patients when they get older.
Keywords: Bipolar, Hyperuricemia, Metabolic syndrome, Ageing

Background
Bipolar disorder is a chronic mental illness, which is
associated with a potentially devastating long-term
impact on the patient’s health, as well as their job, social
relationships and families [1–3]. The World Health
Organization reported that bipolar disorder was the
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seventh among severe diseases in the year 2000 [4].
People suffering from bipolar disorders have high
mortality, which could result in a 10–20 year shorter
lifespan compared to the general population [5]. These
patients have a high prevalence of cardiovascular disease
to which 35–40% of deaths are attributable, which is
associated with metabolic syndrome [6]. Increased ageing population leads to high burden of bipolar disorder
patients [2]. Therefore, it is important to investigate possible contributing factors in order to prevent metabolic
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syndrome, reduce cardiovascular risk, and allocate
health care resources to bipolar patients.
Metabolic syndrome is characterized by visceral obesity,
altered lipid and glucose profiles and hypertension, all of
which are known to increase the risk of developing cardiovascular diseases and type 2 diabetes [7]. Although the
causal factors of developing metabolic syndrome in
bipolar disorder patients are largely unknown, some
contributing factors are proposed. For example, the risk
factors may be due to the side effects of an unhealthy lifestyle including excessive food intake and reduced energy
expenditure caused by mental illness or drug treatment,
or inability to access appropriate health care [8–10].
Uric acid is the final oxidative product in the degradation of purine nucleotides. It has been evidenced by
several studies that high serum uric acid levels were as a
potential causal factor leading to high prevalence of
metabolic syndrome and its components, including
central obesity, hypertension, hyperlipidemia, diabetes,
and insulin resistance [11–13]. Recently, clinical studies
have confirmed that bipolar patients in all phases of the
illness, especially manic episode, had increased serum
uric acid levels [14–16]. Study also shows that the
estimated effect between bipolar disorder and uric acid
levels was partially mediated by metabolic abnormalities
[17]. Therefore, the hyperuricemia and metabolic syndrome may reciprocally affect each other, which impairs
glucose and lipid metabolism. This study investigated
the relationship between hyperuricemia and metabolic
syndrome and its components in individuals suffering
from bipolar disorder.

Methods
Subjects

This study was carried out in Beijing Hui-Long-Guan
hospital, a city-owned psychiatric hospital, China. A total
of 318 patients (male/female = 150/168) were recruited
from the inpatients suffering bipolar disorders. The
study was conduction from July 2015 to June 2017. Patients were diagnosed as bipolar disorder based on
DSM-IV diagnostic criteria for Bipolar Disorder I/II. Patients were referred by their psychiatrists to our research
team. Patients were between 18 and 65 years of age and
Han ethnic Chinese, agreed to participate in the study,
and signed consent form either themselves or the first
degree of their relative if the patient’s condition did not
allow him or her to do so. The research team evaluated
the patients including their disease history, current
symptoms, and general conditions. Those patients excluded were: 1) diagnosed with substance abuse within
the previous 3 months, 2) pregnant or breast-feeding,
and 3) those suffering from a neural degenerative disease
including dementia and mental retardation.
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One hundred and sixty healthy controls (male/female
= 74/86) having no significant differences in age (± 1
year) and gender ratio to the patients were recruited
from the same local community through the advertisement in media and pamphlets distributed to local
residents (Table 1). We have performed psychiatric
examination to all participants. Controls having a history
of mental illness or substance abuse were excluded. The
protocol of this study was approved by the Human
Ethics Committee of Beijing Hui-Long-Guan Hospital
and all patients were provided with a written informed
consent in accordance with National Health and Medical
Research Council Guidelines.
Assessment

The height and weight of all subjects were measured on
the same calibrated weight scale standing barefoot with
light clothes. Body mass index was calculated for all
subjects. Patients with a BMI ≥25 kg/m2 were considered
overweight [18]. Waist circumference was measured at
the mid-point level between the inferior costal margin
and superior iliac crest at the time that the subject was
at the end of his/her expiration while standing. A standard mercury manometer was used to measure blood
pressure with the patient in a supine position. We recorded two readings with 5 min apart for blood pressure
recordings. If one of the two blood pressure readings
were greater than 130/85 mmHg, we took a third
reading 30 min later. We then used the lowest of three
readings in the analysis according to a previous study
[19]. All subjects underwent venipuncture between 6:00
am and 7:00 am after overnight fasting (~ 12 h), and the
blood samples were analyzed on the same day. Serum
concentrations of blood glucose, triglycerides, high-density
lipoprotein cholesterol, and uric acid were measured
using commercial kits (Beckman Coulter, Brea, California,
USA) and an OLYMPUS AU 2700 automatic biochemical analyzer.
The definition of metabolic syndrome and hyperuricemia

The present study used NCEP ATP-III-A for the diagnosis of metabolic syndrome [20]. This is because it has
adjusted waist circumference for those of European
descent to be more appropriate for Asian waist size [20]
and sets a more stringent fasting glucose concentration
to 5.6 mmol/L [21]. NCEP-ATP-III-A criteria requires
the presence at least three of the following components:
1) increased waist circumference (WC): WC greater than
90 cm in men or 80 cm in women; 2) hypertriglyceridemia: triglycerides greater than 1.70 mmol/L (150
mg/dL); 3) high density lipoprotein cholesterol (HDL-C):
HDL-C lower than 1.03 mmol/L (40 mg/dL) in men or
1.29 mmol/L (50 mg/dL) in women; 4) hypertension:
blood pressure greater than 130 mmHg systolic or
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Table 1 Socio-demographic and clinical characteristics of bipolar patient and health control groups
Variable

Patient Group
(n = 318)

Control Group
(n = 160)

X2 /t

p

Age (years)

39.2 ± 13.1

38.5 ± 11.3

0.532

0.595

Male, n (%)

150 (47.2)

74 (46.3)

0.006

0.807

Education (years)

11.8 ± 3.5

11.7 ± 3.9

0.481

0.631

Married, n (%)

175 (55.0)

108 (67.5)

6.852

0.009

Smoker, n (%)

86 (27.0)

26 (16.3)

6.913

0.009

BMI(kg/m2)

24.8 ± 3.3

23.3 ± 2.6

4.955

< 0.001

Overweight, n (%)

145 (45.6)

48 (30.0)

10.757

0.001

Diastolic BP (mm Hg)

75.2 ± 8.4

73.8 ± 8.1

1.793

0.074

Systolic BP (mm Hg)

114.6 ± 11.1

113.5 ± 11.1

1.046

0.296

Hypertension, n (%)

91 (28.6)

29 (18.1)

6.231

0.013

WC (cm)

87.5 ± 11.1

83.6 ± 8.9

3.844

< 0.001

Increased WC, n (%)

186 (58.5)

53 (33.8)

26.062

< 0.001

HDL-C (mmol/L)

1.2 ± 0.4

1.3 ± 0.4

3.331

0.001

Low HDL-C, n (%)

151 (47.5)

50 (31.3)

11.512

0.001

Triglyceride (mmol/L)

2.4 ± 1.5

1.4 ± 1.1

6.526

< 0.001

Hypertriglyceridemia, n (%)

118 (37.1)

37 (23.1)

9.497

0.002

FBG (mmol/L)

5.0 ± 1.2

4.8 ± 0.7

2.660

0.008

Hyperglycaemia, n (%)

75 (23.6)

22 (13.8)

6.365

0.012

MetS, n (%)

135 (42.5)

35 (21.9)

19.669

< 0.001

UA (mmol/L)

348.5 ± 91.8

300.2 ± 76.6

5.729

< 0.001

Hyperuricemia

88 (27.7)

19 (11.9)

15.290

< 0.001

Data were mean ± SD unless otherwise indicated. BMI: body mass index; BP blood pressure, WC waist circumference, HDL-C high density lipoprotein cholesterol,
FBG fasting blood glucose, MetS metabolic syndrome, UA uric acid

greater than 85 mmHg diastolic; and 5) hyperglycemia:
fasting glucose concentration greater than 5.6 mmol/L
(100 mg/dL), or diagnosed as type 2 diabetes. In
addition, treatment with specific drugs was also considered including triglyceride, cholesterol, and glucose
lowering drugs and blood pressure lowering drugs.
Hyperuricemia was defined as serum level of uric acid >
420 μmol/L (7.0 mg/dL) for men and > 360 μmol/L (6.0
mg/dL) for women [22, 23].

hyperuricemia as responding variable. Odds ratios and
95% confidence intervals for all independent variables
were determined. Sample size calculation was set at an
alpha value of 0.05, power 85% based on a previous
study [24]. Marital status, illness duration, and illness
episode were eliminated as confounding factors. All statistical tests were two-tailed, with alpha level set at 0.05.

Results
Demographic and clinical characteristics of subjects

Statistical analysis

Statistical analysis was carried out using SPSS 15.0 for
Windows (SPSS Inc., Chicago, USA). Demographics,
clinical measures, and laboratory values were reported
using measures of means and standard deviation. Group
difference was compared using t-test for continuous variables having normal distribution and Mann-Whitney
test for variables, which were not normal distribution including triglyceride, illness duration and CPZ equivalent
dose. Chi-square test was used for categorical variable
analyses. Univariate analysis was used to identify significant association between variables and metabolic
syndrome. Simple binary logistic regression was used to
establish correlation of metabolic syndrome and

A total of 362 inpatients suffering from bipolar disorders
were enrolled in this study. Forty-four patients (12.2%)
were excluded since there were no fasting blood and/or
anthropometry data such as body weight, height, blood
pressure, and waist circumference. Patients (n = 318) and
control subjects (n = 160) had no significant differences
in age and gender ratio (p > 0.05). Demographic and
clinical characteristics of the study population were
shown in Table 1.
The bipolar patient group had lower marriage rate (p
= 0.009) and higher proportion of smokers (p < 0.01)
than the control group. Patients suffering from bipolar
disorders were overweight (p = 0.001), high BMI (p <
0.001), larger WC (p = 0.013), and low serum HDL-C
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(p = 0.001), increased triglyceride (p < 0.001), high
fasting blood glucose (p = 0.002), and increased uric
acid (p < 0.001) compared to control subjects without
bipolar disorder. There were no statistical differences in
systolic and diastolic blood pressures between patients
and control subjects (both p > 0.05).
Bipolar patients had high prevalence of metabolic
syndrome and hyperuricemia

The prevalence of both hyperuricemia and metabolic
syndrome was higher in bipolar patients compared to
control subjects (27.7% vs. 11.9%, p < 0.001 and 42.5%
vs. 21.9%, p < 0.001). Patients having metabolic syndrome had increased WC (58.5%), hypertriglyceridemia
(37.1%), hyperglycemia (23.6%), and hypertension
(28.6%) and decreased HDL-C (47.5%) (Table 1). Bipolar
patients had high prevalence of hyperuricemia than
control subjects (27.7% vs 11.9%, p < 0.001).
Factors associated with metabolic syndrome and
hyperuricemia

Hyperuricemia and metabolic syndrome in bipolar patients were associated with overweight, longer duration
of the illness, and manic or mixed episodes (all p < 0.05).
Metabolic syndrome was associated with ageing and uses
of mood stabilizer and antipsychotics (all p < 0.05)
(Table 2). Hyperuricemia was more common in male
patients than female patients (p < 0.05). Bipolar patients
with hyperuricemia had a high prevalence of metabolic
syndrome than bipolar patients without hyperuricemia

(Table 3). Hyperuricemia was associated with
hypertriglyceridemia and hyperglycemia, but not with
hypertension, in bipolar patients.
Association between metabolic syndrome and
hyperuricemia

The factors that correlated with the presence of metabolic syndrome were ages including 30 and 49 years
(OR = 2.2, CI95[1.1–4.2], > 50 years (OR = 8.6, CI95[4.1–
18.0], overweight (OR = 3.0, CI95[1.8–5.5]), antipsychotic use (OR = 3.6, CI95[1.7–7.5]), mood stabilizer
use (OR = 2.4, CI95[1.1–5.3]) and hyperuricemia (OR =
3.0, CI95[1.7–5.4]) (Table 4). The hyperuricemia were
higher with increased WC (OR = 2.1, CI95[1.2–4.0]) and
hypertriglyceridemia (OR = 1.9, CI95[1.1–3.1]) (Table 5).
Bipolar patients having hyperuricemia and age greater
than 50 years were more prone to develop metabolic
syndrome (OR = 14.0, CI95[5.0–38.8]) (Fig. 1).

Discussion
The prevalence of metabolic syndrome in bipolar
patients varies significantly from 8.5 to 67% from study
to study reported in the literature [24–28]. A possible
explanation for such large discrepancies may be due to
different ethnicities, regions, dietary habits, and genetic
backgrounds of patients investigated [29]. For example,
high prevalence (67%) was reported in an Australian
study and 53% prevalence in an Indian study in bipolar
patients suffering metabolic syndrome [25, 27]. Low
prevalence of metabolic syndrome in bipolar patients

Table 2 Characteristics of bipolar patients with metabolic syndrome and hyperuricemia
Variable

Metabolic syndrome

Hyperuricemia
p

Yes (n = 86)

No (n = 232)

p

Yes (n = 135)

No (n = 183)

Age (years)

44.1 (12.5)

35.4 (12.6)

< 0.001

40.5 (13.4)

38.6 (13.0)

0.265

Male, n (%)

67 (49.6)

83 (45.4)

0.450

50 (56.8)

100 (43.5)

0.033

Education (years)

11.5 (3.6)

12.10 (3.4)

0.104

11.4 (3.2)

12.0 (3.5)

0.150

Smoker, n (%)

42 (31.1)

44 (24.0)

0.161

26 (29.5)

60 (26.1)

0.534

Married, n (%)

83 (61.5)

92 (50.3)

0.047

47 (53.4)

128 (55.7)

0.719

Illness duration (year)

15.9 (11.3)

9.9 (9.3)

< 0.001

14.25 (10.6)

11.9 (10.6)

0.013

Over weight, n (%)

85 (63.0)

60 (32.8)

< 0.001

52 (59.1)

93 (40.4)

0.003

Illness episode, n (%)

0.012

0.001

Manic/hypomanic

91 (67.4)

104 (56.8)

68 (77.3)

127 (55.2)

Depressive

31 (23.0)

69 (37.7)

14 (15.9)

86 (37.4)

Mixed

5(3.7)

1 (0.5)

3 (3.4)

3 (1.3)

Euthymic

8(5.9)

9(4.9)

3 (3.4)

14 (6.1)

BPD type II, n (%)

9 (6.7)

12 (6.6)

0.969

6 (6.8)

15 (6.5)

0.924

Antipsychotics use, n (%)

120 (88.9)

135 (73.8)

0.001

72 (81.8)

183 (79.6)

0.652

CPZ equivalents (mg/d)

344.7 (205.9)

297.7 (248.1)

0.030

3602 (209.8)

307.0 (236.1)

0.081

Mood stabilizer use, n (%)

118 (87.4)

144 (78.7)

0.044

74 (84.1)

188 (81.7)

0.662

Data were mean ± SD unless otherwise indicated. BPD bipolar disorder, CPZ chlorpromazine
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Table 3 Association between hyperuricemia and metabolic
syndrome and its components

Table 5 Associations between WC and hypertriglyceridemia
with the risk of having hyperuricemia
Variable

OR

95%CI

p

Increased WC

2.128

1.233–4.034

0.007

Hypertriglyceridemia

1.870

1.112–3.121

0.017

X2

p

80 (34.8)

20.015

< 0.001

63 (71.6)

123 (53.5)

8.600

0.003

WC waist circumference

Low HDL-C, n (%)

47 (53.4)

104 (45.2)

1.713

0.191

Hypertriglyceridemia, n (%)

44 (50.0)

74 (32.2)

8.666

0.003

Hypertension, n (%)

30 (34.1)

61 (26.5)

1.785

0.182

Hyperglycaemia, n (%)

29 (33.0)

46 (20.0)

5.927

0.015

Variable

Hyperuricemia
Yes(n = 86)

No(n = 232)

MetS, n (%)

55 (62.5)

Increased WC, n (%)

MetS metabolic syndrome, WC waist circumference, HDL-C high density
lipoprotein cholesterol

was reported in French (18.5%) and Spanish (22.4%)
studies [24, 26]. There are two other Indian studies
reports that the prevalence of metabolic syndrome in
bipolar patients is about 40%, [20, 30], which is similar to 42% found in this study. On the other hand,
the prevalence of metabolic syndrome in control
subjects was 21.9% in the present study, which was
similar to previous Chinese studies in normal population (24.5%) [31].
Visceral obesity should be closely monitored as the
prevalence of larger WC was significantly higher in
bipolar patients than control subjects (58.5% vs 33.8%).
Visceral obesity is associated with metabolic syndrome,
type 2 diabetes and coronary heart disease [32]. The
prevalence of metabolic syndrome in bipolar patients
was about eight times higher in the bipolar patients with
age over 50 years than the bipolar patients with age less
than 30 years. This could be due to increased uric acids,
which worse insulin sensitivity in elderly patients. Patients having longer illness duration and experiencing
manic or mixed episodes had higher rates of metabolic
syndrome. The prevalence of gender difference having
metabolic syndrome in bipolar patients is controversial.
Some studies have reported that the prevalence of metabolic syndrome in male bipolar patients was about twice
higher than female patients; but negative and opposite
Table 4 Associations between the various factors and the risk
of having metabolic syndrome
Variable

OR

95%CI

p

< 30 years of age

1.000

Reference

–

30–49 years of age

2.149

1.122–4.177

0.021

≥50 years of age

8.587

4.087–18.044

< 0.001

BMI ≥25 kg/m2

3.005

1.767–5.110

< 0.001

a

Antipsychotics

3.595

1.722–7.497

0.001

Mood stabilizerb

2.397

1.087–5.285

0.030

3.029

1.685–5.443

< 0.001

c

Hyperuricemia
a:

use of antipsychotic drug at clinical dose, b: use of mood stabilizer at clinical
dose, c: serum uric acid > 420 μmol/l for men and > 360 μmol/l for women [21]

results were also reported in other studies [27, 33, 34].
The data presented in this study suggested no gender
differences to develop metabolic syndrome in bipolar patients. About 80% of bipolar patients were prescribed
atypical antipsychotic drugs and/or mood stabilizes,
which were strongly linked to metabolic syndrome found
in the current study.
Our results confirmed previous data that serum uric
acid concentrations in bipolar patients were significantly
higher than healthy controls [15, 17, 35]. Animal study
shows that uric acid induces endothelial dysfunction and
overproduction of reactive oxygen species, which has
been considered as a major factor of insulin resistance
[36]. In humans, hyperuricemia is also associated with
insulin resistance and metabolic syndrome [37, 38]. It is
possible that elevated uric acid worse insulin sensitivity
and metabolic syndrome and vice versa. Both hyperuricemia and metabolic syndrome increase the risk of
cardiovascular disease and dementia in elderly people
[39]. Ageing is not necessarily associated increased blood
uric acid [40]. This study showed that bipolar patient
with hyperuricemia and over 50 years of age have very
high prevalence for metabolic disorders and its components. Therefore, a special caution should be taken for
preventing cardiovascular diseases when there is hyperuricemia in elderly bipolar patients.
Prevention and treatment of hyperuricemia are clearly
important in terms of reducing the prevalence of
metabolic syndrome in patients suffering from bipolar
disorder. Since metabolic syndrome increases the risks
of a number of life threatening diseases, reinstalling
hyperuricemia back to normal level may help to reduce diabetes and kidney and cardiovascular diseases
in these patients.
This study has some limitations. First, only inpatients
with bipolar disorder were included, who tend to suffer
more severely, have more comorbidities, and higher
rates of pharmacological treatment than those of outpatients. Therefore, our data do not necessarily reflect the
prevalence of metabolic syndrome of outpatients suffering from bipolar disorder. Second, antidepressant (eg:
mirtazapine) uses were not obtained in this study, which
could cause weight gain and metabolic disorders [41].
Finally, other possible confounding factors were not
ruled out, which could play a role contributing to the
development of metabolic syndrome including types and

Chen et al. BMC Psychiatry

(2018) 18:390

Page 6 of 7

Fig. 1 Shows interaction between age ≥ 50 years of age or < 50 years of age and hyperuricemia for metabolic syndrome. Odd ratios are based on
95% confidence interval

duration of antipsychotic drugs used, diet, physical
activity, socioeconomic status, and alcohol use.

Conclusions
Hyperuricemia is more common in bipolar patients with
metabolic syndrome. The high prevalence of metabolic
syndrome and hyperuricemia may be due to hyperglycemia, ageing, antipsychotic and mood stabilizer uses,
illness duration, and visceral obesity. It is possible that
elevated uric acid disrupts metabolic regulation and on
the other hand, metabolic disorders could further worse
hyperuricemia in bipolar patients. Bipolar patients with
hyperuricemia and age greater than 50 years were highly
prone to develop metabolic syndrome.
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